Ultragenyx Pharmaceutical Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RARE research report →
About the company
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets.
- CEO
- Emil D. Kakkis
- IPO
- 2014
- Employees
- 1,294
- HQ
- Novato, CA, US
Price Chart
- Market Cap
- $3.30B
- P/E
- -5.48
- P/S
- 4.92
- P/B
- -14.27
- EV/EBITDA
- -8.59
- Div Yield
- 0.00%
- Gross Margin
- 83.57%
- Op Margin
- -83.92%
- Net Margin
- -91.03%
- ROE
- 1566.94%
- ROIC
- -53.86%
- Revenue
- $673.00M · 20.13%
- Net Income
- $-575,000,000 · -1.02%
- EPS
- $-5.83 · 7.31%
- Op Income
- $-535,000,000
- FCF YoY
- -11.93%
- 52W High
- $42.37
- 52W Low
- $18.29
- 50D MA
- $25.48
- 200D MA
- $27.02
- Beta
- 0.31
- Avg Volume
- 2.12M
Get TickerSpark's AI analysis on RARE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | Sanders Corazon (Corsee) D. | sell | 2,000 |
| Jun 15, 26 | Parschauer Karah Herdman | sell | 1,899 |
| Jun 1, 26 | Horn Howard | sell | 4,653 |
| May 14, 26 | Fust Matthew K | other | 7,751 |
| May 14, 26 | Fust Matthew K | other | 14,058 |
| May 14, 26 | SULIMAN SHEHNAAZ | other | 7,751 |
| May 18, 26 | SULIMAN SHEHNAAZ | sell | 5,740 |
| May 14, 26 | SULIMAN SHEHNAAZ | other | 14,058 |
| May 14, 26 | Ray Amrit | other | 7,751 |
| May 14, 26 | Ray Amrit | other | 14,058 |
Our RARE coverage
Recent articles, reports, and earnings notes.
No research on RARE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RARE report →Similar companies
Peers in the same neighborhood.